Literature DB >> 4391785

Human cardiovascular effects of alprenolol, a beta-adrenergic blocker: hemodynamic, antiarrhythmic, and antianginal.

A J Wasserman, J D Proctor, F J Allen, V E Kemp.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1970        PMID： 4391785

Source DB:  PubMed          Journal:  J Clin Pharmacol J New Drugs        ISSN： 0095-9863


× No keyword cloud information.
  6 in total

1.  Central haemodynamic effects in man of intravenous d-alprenolol during rest and exercise.

Authors:  L G Ekelund; A Melcher; L Orö
Journal:  Eur J Clin Pharmacol       Date:  1971-09       Impact factor: 2.953

2.  How intrinsic sympathomimetic activity modulates the haemodynamic responses to beta-adrenoceptor antagonists. A clue to the nature of their antihypertensive mechanism.

Authors:  A J Man in 't Veld; M A Schalekamp
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

3.  Lidoflazine: double-blind trial of a new coronary vasodilator in angina pectoris.

Authors:  B Brantmark; N Egelius; E Fabricius; M Jemt; G Palmborg; J Philipson; N Rönnegård
Journal:  Eur J Clin Pharmacol       Date:  1973-10       Impact factor: 2.953

Review 4.  Pharmacodynamic properties of beta-adrenergic receptor blocking drugs in man.

Authors:  D G Gibson
Journal:  Drugs       Date:  1974       Impact factor: 9.546

Review 5.  Beta-adrenergic receptor blocking drugs in angina pectoris.

Authors:  B N Prichard
Journal:  Drugs       Date:  1974       Impact factor: 9.546

Review 6.  Beta-adrenergic receptor blocking drugs in cardiac arrhythmias.

Authors:  B N Singh; D E Jewitt
Journal:  Drugs       Date:  1974       Impact factor: 9.546
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.